Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics
Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.
Sphere Fluidics has announced an investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf, for reliable and highly stable droplet generation and processing. Sphere Fluidics will expand operations to meet demand for large-scale commercial supply of its high-performing surfactant for use in a wide range of microfluidic application workflows.
Pico-Surf is a high-quality and animal-origin-free biocompatible surfactant optimized to support the formation of aqueous solution-in-oil picodroplets. Sphere Fluidics aims to increase production of Pico-Surf by three-fold in 2020, while maintaining its industry-leading standards, through significant investment of resources in manufacture and quality control processes, and workforce. As part of the company's range of specialist chemicals, Pico-Surf is designed to work effectively and flexibly across a broad range of microfluidic systems, including the Sphere Fluidics' proprietary single cell analysis platforms and applications, such as molecular biology assays, cell secretion assays and cell growth studies.
The unique and patented molecular structure of Pico-Surf stabilizes droplets, and retains and protects their cellular and molecular contents over a wide range of temperatures and biological conditions, helping to ensure high cell viability for improved assay performance. Droplets generated using Pico-Surf show low end point interfacial tension and critical micelle concentration in comparison to other commercially available surfactants. The purity and quality of the surfactant also enables a more efficient droplet sorting process at low voltage. The ready-to-use surfactant is available in large batches or made-to-order with ensured lot-to-lot consistency.
Dr Marian Rehak, Vice President of Research and Development, Sphere Fluidics, said: “We are enthused by the increased demand for Pico-Surf, and eager to mobilize its production to meet demand. While doing so, we will ensure its very high-quality control standards are maintained, meaning researchers can continue to rely on Pico-Surf to create droplets that are stable and reproducible.”
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Sphere Fluidics’ world-leading expertise in picodroplet technology has enabled the development of an ever-growing range of high-performing patented consumables, vital for the successful use of microfluidic systems. All our consumable products have been designed to be platform-agnostic, so they work effectively with a number of microfluidic systems.”
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance